IPP Bureau
Dr Julie L. Gerberding to retire from Merck as Chief Patient Officer
By IPP Bureau - March 02, 2022
Earlier today, the Foundation for the National Institutes of Health (FNIH) announced that Dr. Gerberding will become CEO of the FNIH on May 16
Amrita University launches wearable device for home monitoring of glucose and BP
By IPP Bureau - March 02, 2022
Patients can use the wearable, non-invasive device to measure six body parameters including blood glucose, blood pressure, heart rate, blood oxygen, respiratory rate and 6-lead ECG, from the comfort of their home
Univar Solutions opens latest Solution Centre for its global ecosystem of innovation
By IPP Bureau - March 02, 2022
State-of-the-art laboratory to support ingredient and specialty chemical innovation, product formulation application development and more sustainable solutions across Europe and beyond
USFDA approves first generic version of Apokyn cartridges
By IPP Bureau - March 02, 2022
TruPharma has commenced commercial marketing of Sage's approved generic cartridge product
Amneal enters U.S. biosimilars market with approval of Releukotm
By IPP Bureau - March 02, 2022
First of three Amneal biosimilars expected for U.S. approval and launch in 2022
Serina Fischer appointed GM India at Takeda Pharmaceuticals
By IPP Bureau - March 02, 2022
Serina has over 17 years of experience in the biopharmaceutical industry
Trivitron Healthcare acquires U.S. based The Kennedy Company
By IPP Bureau - March 02, 2022
This has further strengthened its manufacturing presence in the United States of America
Singapore first to top WHO’s classification of medical regulator
By IPP Bureau - March 01, 2022
Achieving ML 4 brings Singapore closer to becoming a WHO listed authority, a new scheme that will be operational later this year and will list the world’s regulators of reference
Medvarsity partners with Clove Dental to launch Fellowship in Endodontics
By IPP Bureau - March 01, 2022
110 BDS graduates admitted in week one of the launch
Bristol Myers Squibb’s application for Opdivo plus chemotherapy receives USFDA priority review
By IPP Bureau - March 01, 2022
If approved, Opdivo plus chemotherapy would be the first neoadjuvant immunotherapy-based option for patients with resectable non-small cell lung cancer in the U.S.
Novavax UK Phase 3 trial demonstrates protection from Covid-19 over six-month period
By IPP Bureau - March 01, 2022
High level of vaccine efficacy maintained over a 6-month period of surveillance
Boehringer Ingelheim partners with Lifebit to capture health data
By IPP Bureau - March 01, 2022
This collaboration aims at capturing translational disease insights from large external healthcare biobanks and maximizing value of data for drug discovery and precision medicine
AstraZeneca and Neurimmune enter licencing agreement to develop and commercialise NI006
By IPP Bureau - March 01, 2022
Under the terms of the agreement, the upfront payment from Alexion to Neurimmune is US $ 30m
Innovent Biologics and AnHeart Therapeutics receive NMPA breakthrough designation for taletrectinib
By IPP Bureau - March 01, 2022
The NMPA Breakthrough Therapy Designation was based on results from the Phase 2 TRUST trial of ROS1 fusion-positive NSCLC patients treated with taletrectinib, a new generation of potent ROS1 inhibitors
Bruker releases CCS-Enabled TIMScore and TIMS DIA-NN 4D Proteomics Software
By IPP Bureau - March 01, 2022
Innovative TIMScore for dda-PASEF and dia-PASEF libraries, combined with TIMS DIA-NN identifies 9000 protein groups from 200 ng K562 lysate in just 35 min gradient
